BMS, Nektar Ink Up-to-$3.6B Immuno-Oncology Combination Therapy Collaboration

Bristol-Myers Squibb (BMS) will partner with Nektar Therapeutics on a combination cancer immunotherapy collaboration that could generate up to $3.6 billion-plus for Nektar—potentially the second-most-valuable immuno-onoclogy partnership ever launched.The companies agreed to co-develop Nektar’s lead immuno-oncology program NKTR-214 in combination with BMS’ marketed cancer immunotherapy Opdivo ® (nivolumab), as well as a combination of NKTR-214 with both Opdivo and BMS’